
What’s coming in 2026 is about to reshape breast oncology.In Episode 2, Dr. Jason Mouabbi and Dr. Paolo Tarantino go beyond published data to tackle the tough questions about what's next. They break down the evolving landscape of KEYNOTE-756, the rise of oral SERDs in the first line, and the role of HER2DX. From T-DXd in early disease and CNS risk in HER2+, to the promise of improving outcomes in triple-negative breast cancer, they are laying out the roadmap for the future of care.The landscape is moving fast. Listen in as we prepare for the next wave of practice-changing data.▶️ Watch on YouTube - https://youtu.be/Skt3jGMBncM🎧 Listen on Spotify, Apple Podcasts, iHeartRadio, CastBox, & Amazon Music#BreastCancer #Oncology #OncologyPodcast #ClinicalTrials #CancerResearch #HER2Positive #TripleNegative #OralSERD #ADCs #MedicalOncology #MedEd #CancerCare
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

The Breast Friends Podcast Ep. 5 | Dr. Hope Rugo: The Evolution of Breast Oncology

The Breast Friends Podcast Ep. 4 | The Future of Breast Cancer Treatment

The Breast Friends Podcast Ep. 3 | Breast Cancer Trial Madness

The Breast Friends Podcast Ep. 1 | Breaking the Status Quo: New Frontiers in Breast Cancer Care
Free AI-powered recaps of The Breast Friends Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.